| Expression pattern: |
DN |
| Associated gene: |
SIRT1 |
| Associated microRNA: |
miR-145 |
| Biological function: |
promotes INS-1 cell proliferation and insulin secretion under glucolipotoxicity and inhibits apoptosis, alleviating beta-cell dysfunction in T2DM context |
| Molecular mechanism: |
Acts as a ceRNA/miRNA sponge for miR-145 to relieve repression of SIRT1, thereby increasing SIRT1 expression |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Transfection; CCK8; Annexin V/PI Flow Cytometry; ELISA; Western Blot; Luciferase Reporter Assay; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
Potential novel diagnostic marker and therapeutic target for T2DM |
| Description: |
hsa_circ_0115355 (also referred to as circCSE1L) is down-regulated in T2DM patient serum and in high-glucose-treated INS-1 cells. Functionally, it protects beta-cell models from glucolipotoxicity by promoting proliferation and insulin secretion and inhibiting apoptosis, mainly via a ceRNA mechanism in which it sponges miR-145 to upregulate SIRT1. |
| Confidence score: |
0.7884 |